BACKGROUND: To evaluate the efficacy of suppressing a recurrence of Toxoplasma retinochoroiditis after treatment with atovaquone. METHODS: Retrospective, nonrandomized, clinical trial. Forty-one immunocompetent patients were treated for Toxoplasma retinochoroiditis with atovaquone between 1999 and 2006. The diagnosis was based on clinical signs alone. Atovaquone was given 750 mg two to three times daily together with oral steroids. Lesion location, time interval until recurrence, visual function, and adverse events were recorded. RESULTS: Forty-two eyes of 41 patients were treated with atovaquone for Toxoplasma retinochoroiditis. Side-effects were usually mild and only one patient stopped therapy with atovaquone because of nausea. Reactivation of retinochoroiditis occurred in 18 patients (44%) during a time interval of 3-70 months. CONCLUSIONS: The therapy of Toxoplasma retinochoroiditis with atovaquone is well tolerated. Our data suggests that therapy with atovaquone has the potential to prolong the time to recurrence of Toxoplasma retinochoroiditis. A prospective randomized comparative long-term clinical trial would be necessary to confirm our data.
BACKGROUND: To evaluate the efficacy of suppressing a recurrence of Toxoplasma retinochoroiditis after treatment with atovaquone. METHODS: Retrospective, nonrandomized, clinical trial. Forty-one immunocompetent patients were treated for Toxoplasma retinochoroiditis with atovaquone between 1999 and 2006. The diagnosis was based on clinical signs alone. Atovaquone was given 750 mg two to three times daily together with oral steroids. Lesion location, time interval until recurrence, visual function, and adverse events were recorded. RESULTS: Forty-two eyes of 41 patients were treated with atovaquone for Toxoplasma retinochoroiditis. Side-effects were usually mild and only one patient stopped therapy with atovaquone because of nausea. Reactivation of retinochoroiditis occurred in 18 patients (44%) during a time interval of 3-70 months. CONCLUSIONS: The therapy of Toxoplasma retinochoroiditis with atovaquone is well tolerated. Our data suggests that therapy with atovaquone has the potential to prolong the time to recurrence of Toxoplasma retinochoroiditis. A prospective randomized comparative long-term clinical trial would be necessary to confirm our data.
Authors: Lotje E H Bosch-Driessen; Tos T J M Berendschot; Jenny V Ongkosuwito; Aniki Rothova Journal: Ophthalmology Date: 2002-05 Impact factor: 12.079
Authors: P E Rolan; A J Mercer; B C Weatherley; T Holdich; H Meire; R W Peck; G Ridout; J Posner Journal: Br J Clin Pharmacol Date: 1994-01 Impact factor: 4.335
Authors: J Stone Doggett; Aaron Nilsen; Isaac Forquer; Keith W Wegmann; Lorraine Jones-Brando; Robert H Yolken; Claudia Bordón; Susan A Charman; Kasiram Katneni; Tracey Schultz; Jeremy N Burrows; David J Hinrichs; Brigitte Meunier; Vern B Carruthers; Michael K Riscoe Journal: Proc Natl Acad Sci U S A Date: 2012-09-10 Impact factor: 11.205
Authors: Martin McPhillie; Ying Zhou; Kamal El Bissati; Jitender Dubey; Hernan Lorenzi; Michael Capper; Amanda K Lukens; Mark Hickman; Stephen Muench; Shiv Kumar Verma; Christopher R Weber; Kelsey Wheeler; James Gordon; Justin Sanders; Hong Moulton; Kai Wang; Taek-Kyun Kim; Yuqing He; Tatiana Santos; Stuart Woods; Patty Lee; David Donkin; Eric Kim; Laura Fraczek; Joseph Lykins; Farida Esaa; Fatima Alibana-Clouser; Sarah Dovgin; Louis Weiss; Gael Brasseur; Dyann Wirth; Michael Kent; Leroy Hood; Brigitte Meunieur; Craig W Roberts; S Samar Hasnain; Svetlana V Antonyuk; Colin Fishwick; Rima McLeod Journal: Sci Rep Date: 2016-07-14 Impact factor: 4.379
Authors: Jenni A Hayward; Esther Rajendran; Soraya M Zwahlen; Pierre Faou; Giel G van Dooren Journal: PLoS Pathog Date: 2021-02-01 Impact factor: 6.823